146 related articles for article (PubMed ID: 38010951)
21. Targeting the undruggable: menin inhibitors ante portas.
Dempke WCM; Desole M; Chiusolo P; Sica S; Schmidt-Hieber M
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9451-9459. PubMed ID: 37103568
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic implications of menin inhibition in acute leukemias.
Issa GC; Ravandi F; DiNardo CD; Jabbour E; Kantarjian HM; Andreeff M
Leukemia; 2021 Sep; 35(9):2482-2495. PubMed ID: 34131281
[TBL] [Abstract][Full Text] [Related]
23. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
24. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.
Borkin D; He S; Miao H; Kempinska K; Pollock J; Chase J; Purohit T; Malik B; Zhao T; Wang J; Wen B; Zong H; Jones M; Danet-Desnoyers G; Guzman ML; Talpaz M; Bixby DL; Sun D; Hess JL; Muntean AG; Maillard I; Cierpicki T; Grembecka J
Cancer Cell; 2015 Apr; 27(4):589-602. PubMed ID: 25817203
[TBL] [Abstract][Full Text] [Related]
25. Menin-MLL1 Interaction Small Molecule Inhibitors: A Potential Therapeutic Strategy for Leukemia and Cancers.
Shi Q; Xu M; Kang Z; Zhang M; Luo Y
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049787
[TBL] [Abstract][Full Text] [Related]
26. Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias.
Grembecka J; Belcher AM; Hartley T; Cierpicki T
J Biol Chem; 2010 Dec; 285(52):40690-8. PubMed ID: 20961854
[TBL] [Abstract][Full Text] [Related]
27. Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia.
Chen Y; Jones KL; Anastassiadis K; Kranz A; Stewart AF; Grembecka J; Meyerson M; Ernst P
Exp Hematol; 2019 Jan; 69():37-42. PubMed ID: 30315824
[TBL] [Abstract][Full Text] [Related]
28. Novel therapeutic strategies for MLL-rearranged leukemias.
Wong NM; So CWE
Biochim Biophys Acta Gene Regul Mech; 2020 Sep; 1863(9):194584. PubMed ID: 32534041
[TBL] [Abstract][Full Text] [Related]
29. Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/
Bill M; Mrózek K; Kohlschmidt J; Eisfeld AK; Walker CJ; Nicolet D; Papaioannou D; Blachly JS; Orwick S; Carroll AJ; Kolitz JE; Powell BL; Stone RM; de la Chapelle A; Byrd JC; Bloomfield CD
Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26340-26346. PubMed ID: 33020282
[TBL] [Abstract][Full Text] [Related]
30. How to effectively treat acute leukemia patients bearing MLL-rearrangements ?
Steinhilber D; Marschalek R
Biochem Pharmacol; 2018 Jan; 147():183-190. PubMed ID: 28943239
[TBL] [Abstract][Full Text] [Related]
31. Automated CUT&Tag profiling of chromatin heterogeneity in mixed-lineage leukemia.
Janssens DH; Meers MP; Wu SJ; Babaeva E; Meshinchi S; Sarthy JF; Ahmad K; Henikoff S
Nat Genet; 2021 Nov; 53(11):1586-1596. PubMed ID: 34663924
[TBL] [Abstract][Full Text] [Related]
32. Disordered epigenetic regulation in MLL-related leukemia.
Zhang Y; Chen A; Yan XM; Huang G
Int J Hematol; 2012 Oct; 96(4):428-37. PubMed ID: 23054645
[TBL] [Abstract][Full Text] [Related]
33. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).
Fiskus W; Boettcher S; Daver N; Mill CP; Sasaki K; Birdwell CE; Davis JA; Takahashi K; Kadia TM; DiNardo CD; Jin Q; Qi Y; Su X; McGeehan GM; Khoury JD; Ebert BL; Bhalla KN
Blood Cancer J; 2022 Jan; 12(1):5. PubMed ID: 35017466
[TBL] [Abstract][Full Text] [Related]
34. Menin regulates the serine biosynthetic pathway in Ewing sarcoma.
Svoboda LK; Teh SSK; Sud S; Kerk S; Zebolsky A; Treichel S; Thomas D; Halbrook CJ; Lee HJ; Kremer D; Zhang L; Klossowski S; Bankhead AR; Magnuson B; Ljungman M; Cierpicki T; Grembecka J; Lyssiotis CA; Lawlor ER
J Pathol; 2018 Jul; 245(3):324-336. PubMed ID: 29672864
[TBL] [Abstract][Full Text] [Related]
35. NUP98-MLL fusion in human acute myeloblastic leukemia.
Kaltenbach S; Soler G; Barin C; Gervais C; Bernard OA; Penard-Lacronique V; Romana SP
Blood; 2010 Sep; 116(13):2332-5. PubMed ID: 20558618
[TBL] [Abstract][Full Text] [Related]
36. Menin is necessary for long term maintenance of meningioma-1 driven leukemia.
Libbrecht C; Xie HM; Kingsley MC; Haladyna JN; Riedel SS; Alikarami F; Lenard A; McGeehan GM; Ernst P; Bernt KM
Leukemia; 2021 May; 35(5):1405-1417. PubMed ID: 33542482
[TBL] [Abstract][Full Text] [Related]
37. The stem cell-specific long noncoding RNA HOXA10-AS in the pathogenesis of KMT2A-rearranged leukemia.
Al-Kershi S; Bhayadia R; Ng M; Verboon L; Emmrich S; Gack L; Schwarzer A; Strowig T; Heckl D; Klusmann JH
Blood Adv; 2019 Dec; 3(24):4252-4263. PubMed ID: 31867596
[TBL] [Abstract][Full Text] [Related]
38. MEN1 mutations mediate clinical resistance to menin inhibition.
Perner F; Stein EM; Wenge DV; Singh S; Kim J; Apazidis A; Rahnamoun H; Anand D; Marinaccio C; Hatton C; Wen Y; Stone RM; Schaller D; Mowla S; Xiao W; Gamlen HA; Stonestrom AJ; Persaud S; Ener E; Cutler JA; Doench JG; McGeehan GM; Volkamer A; Chodera JD; Nowak RP; Fischer ES; Levine RL; Armstrong SA; Cai SF
Nature; 2023 Mar; 615(7954):913-919. PubMed ID: 36922589
[TBL] [Abstract][Full Text] [Related]
39. Deregulation of the HOXA9/MEIS1 axis in acute leukemia.
Collins CT; Hess JL
Curr Opin Hematol; 2016 Jul; 23(4):354-61. PubMed ID: 27258906
[TBL] [Abstract][Full Text] [Related]
40. Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia.
Tubío-Santamaría N; Jayavelu AK; Schnoeder TM; Eifert T; Hsu CJ; Perner F; Zhang Q; Wenge DV; Hansen FM; Kirkpatrick JM; Jyotsana N; Lane SW; von Eyss B; Deshpande AJ; Kühn MWM; Schwaller J; Cammann C; Seifert U; Ebstein F; Krüger E; Hochhaus A; Heuser M; Ori A; Mann M; Armstrong SA; Heidel FH
Mol Cancer; 2023 Dec; 22(1):196. PubMed ID: 38049829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
